At the end of the latest market close, Inhibikase Therapeutics Inc. (IKT) was valued at $0.66. In that particular session, Stock kicked-off at the price of $0.7975 while reaching the peak value of $0.7975 and lowest value recorded on the day was $0.70. The stock current value is $0.75.Recently in News on March 8, 2023, Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Multiple System Atrophy. – Advancing model studies of IkT-148009 in MSA; early data has shown a substantial neuroprotective benefit in response to c-Abl inhibition by IkT-148009 –. You can read further details here
Inhibikase Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $1.5200 on 03/31/22, with the lowest value was $0.4401 for the same time period, recorded on 11/10/22.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Inhibikase Therapeutics Inc. (IKT) full year performance was -47.89%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Inhibikase Therapeutics Inc. shares are logging -50.97% during the 52-week period from high price, and 69.33% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.44 and $1.52.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1287235 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Inhibikase Therapeutics Inc. (IKT) recorded performance in the market was 49.04%, having the revenues showcasing 49.04% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 19.87M, as it employees total of 6 workers.
The Analysts eye on Inhibikase Therapeutics Inc. (IKT)
During the last month, 0 analysts gave the Inhibikase Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 0.6559, with a change in the price was noted -0.08. In a similar fashion, Inhibikase Therapeutics Inc. posted a movement of -10.22% for the period of last 100 days, recording 242,860 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for IKT is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical rundown of Inhibikase Therapeutics Inc. (IKT)
Raw Stochastic average of Inhibikase Therapeutics Inc. in the period of last 50 days is set at 41.67%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 76.34%. In the last 20 days, the company’s Stochastic %K was 48.93% and its Stochastic %D was recorded 33.44%.
Considering, the past performance of Inhibikase Therapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 49.04%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -18.98%, alongside a downfall of -47.89% for the period of the last 12 months. The shares increased approximately by 4.62% in the 7-day charts and went up by 0.70% in the period of the last 30 days. Common stock shares were driven by 49.04% during last recorded quarter.